Zhuhai Sailong Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
August 25, 2021 at 04:45 pm IST
Share
Zhuhai Sailong Pharmaceutical Co.,Ltd. announced earnings results for the half year ended June 30, 2021. For the half year, the company announced sales was CNY 129.031 million compared to CNY 88.435 million a year ago. Operating income was CNY 12.125 million compared to operating loss of CNY 10.251 million a year ago. Net income was CNY 9.415 million compared to net loss of CNY 13.212 million a year ago. Basic earnings per share from continuing operations was CNY 0.0535 compared to basic loss per share from continuing operations of CNY 0.0751 a year ago.
Sailong Pharmaceutical Group Co Ltd, formerly Zhuhai Sailong Pharmaceutical Co Ltd, is a China-based company principally engaged in the research and development, production and sales of pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and preparations, as well as providing technical services. The Companyâs main products include monosialin tetrahexose ganglioside sodium injections, brain protein hydrolyzate for injections, clindamycin phosphate for injections, pantoprazole sodium for injections and milrinon injections, among others. Through its subsidiaries, the Company is also engaged in the sales of scraps, provision of technical services and sales promotion. The Company mainly conducts its businesses with domestic market.
SAILONG PHARMACEUTICAL GROUP CO.,LTD. 
